Pfizer has voluntarily withdrawn its sickle cell disease therapy Oxbryta (voxelotor) from all global markets after discovering an imbalance in deaths during clinical trials.
Vertex Pharmaceuticals and CRISPR Therapeutics secure FDA approval for Casgevy in transfusion-dependent beta thalassemia (TDT), two months ahead of schedule.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.